A-CLOSEHot Line 3Interventional Cardiology
Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy After High-Risk Coronary Intervention
Clopidogrel monotherapy versus extended dual antiplatelet therapy after high-risk percutaneous coronary intervention
Presenting authorByeong-Keuk KimInterventional / Structural Cardiology · University of SeoulByeong-Keuk Kim is Professor in the Division of Cardiology at Yonsei University College of Medicine and Director of the Cardiac Catheterization and Intervention Department at Severance Cardiovascular Hospital in Seoul, South Korea. He is board-certified in internal medicine and cardiology. He completed a postdoctoral fellowship in invasive coronary imaging at Stanford University Medical Center.
Overview
Await ESC 2026 results before altering post-PCI DAPT; leaves open optimal monotherapy versus extended therapy after high-risk stenting.
Key result
Clopidogrel monotherapy compared with extended dual antiplatelet therapy after high-risk percutaneous coronary intervention currently has pending results from the ESC Congress 2026.
Discussion
Expert reaction lands here the moment A-CLOSE reports.
Key Points
- Evaluation evaluates clopidogrel monotherapy against extended dual antiplatelet therapy after high-risk percutaneous coronary intervention in patients.
- Clinical trial protocol investigates antiplatelet therapy strategies after complex stenting procedures, tracking major ischemic and bleeding events over follow-up.
- Presentation at the medical congress highlights evolving dual antiplatelet therapy regimens, though definitive clinical outcome results remain pending formal release.
Main Result
Absolute Event Rate: 0% vs 0%